Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second-line ramucirumab with or without paclitaxel in elderly patients with advanced gastric or gastroesophageal junction cancer
2017-001683-37Phase 2Active
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Jan 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Ramucirumab monotherapy with Ramucirumab plus paclitaxel (2 arms). Primary endpoints: Six-month survival rate and Quality of life at 4 months. Started Jan 2018; status: active.
02
Drugs
ramucirumabpaclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2017-001683-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001683-37.